IMS 2022 | Improving the efficacy of CAR-T therapy in multiple myeloma through SUMOylation inhibition
Li Du
• 27 Aug 2022
Li Du, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, comments on the impact of SUMOylation inhibition on the efficacy of CAR-T therapy in multiple myeloma. It has been shown that inhibiting SUMOylation prevents T-cell exhaustion and prolongs CAR-T persistence. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
